CEACAM6 Expression is Associated with Immune Infiltration and Poor Prognosis in Esophageal Squamous Cell Carcinoma
10.3971/j.issn.1000-8578.2026.25.0826
- VernacularTitle:CEACAM6表达与食管鳞癌免疫浸润及不良预后的关联
- Author:
Jiahui LI
1
;
Enwei XU
1
;
Wei CUI
1
;
Yuanyuan ZHAO
1
;
Keqing KANG
1
;
Peng BU
1
;
Guohai ZHAO
1
;
Yang ZHOU
1
Author Information
1. Department of Pathology, Shanxi Province Cancer Hospital/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, China.
- Publication Type:CLINICALRESEARCH
- Keywords:
CEACAM6;
Esophageal squamous cell carcinoma;
Tumor microenvironment;
Prognosis;
Immune infiltration
- From:
Cancer Research on Prevention and Treatment
2026;53(3):194-202
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in esophageal squamous cell carcinoma (ESCC) and analyze its correlation with immune cell infiltration and patient prognosis. Methods Three ESCC datasets (GSE161533, GSE26886, and GSE23400) from the GEO database were analyzed to identify differentially expressed genes. CEACAM6 was identified as a key gene through survival analysis. Its expression, prognostic value, and relationship with immune cell infiltration were further explored using databases, such as TIMER. Tissue samples were collected from 162 patients with ESCC. Immunohistochemistry was performed to detect the expression of CEACAM6, immune cell markers (CD4, CD8, CD20, and CD56), and immune checkpoint molecules (HHLA2 and CD40LG). Correlations between CEACAM6 expression and clinicopathological features, immune cell infiltration, and immune checkpoints were analyzed. Results Bioinformatic analysis and clinical sample validation confirmed that CEACAM6 expression was significantly upregulated in ESCC tissues compared with adjacent nontumor tissues (P<0.05). High CEACAM6 expression was closely associated with advanced clinical stage (AJCC Ⅲ-Ⅳ), high T stage (T3-T4), lymph node metastasis, nonulcerative type, and poor prognosis. Furthermore, CEACAM6 expression levels were positively correlated with the infiltration density of CD8+ T cells, CD4+ T cells, and CD20+ B cells within the tumor microenvironment and with the expression of the immune checkpoint molecules HHLA2 and CD40LG (all P<0.05). Conclusion CEACAM6 serves as an independent poor prognostic factor for ESCC. Its high expression is implicated in the modulation of the tumor immune microenvironment by correlating with specific immune cell infiltration and immune checkpoint molecules, suggesting its potential as a novel prognostic biomarker and immunotherapeutic target for ESCC.
